NO991071L - N-substituerte indol-3-glyoksylamid med antiastmatisk, antiallergisk og immunundertrykkende/immunmodulerende virkning - Google Patents

N-substituerte indol-3-glyoksylamid med antiastmatisk, antiallergisk og immunundertrykkende/immunmodulerende virkning

Info

Publication number
NO991071L
NO991071L NO991071A NO991071A NO991071L NO 991071 L NO991071 L NO 991071L NO 991071 A NO991071 A NO 991071A NO 991071 A NO991071 A NO 991071A NO 991071 L NO991071 L NO 991071L
Authority
NO
Norway
Prior art keywords
glyoxylamide
asthmatic
immunosuppressive
allergic
substituted indole
Prior art date
Application number
NO991071A
Other languages
English (en)
Other versions
NO991071D0 (no
NO314725B3 (no
NO314725B1 (no
Inventor
Guillaume Lebaut
Cucilia Menciu
Bernhard Kutscher
Peter Emig
Stefan Szelenyi
Kay Brune
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of NO991071D0 publication Critical patent/NO991071D0/no
Publication of NO991071L publication Critical patent/NO991071L/no
Publication of NO314725B1 publication Critical patent/NO314725B1/no
Publication of NO314725B3 publication Critical patent/NO314725B3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
NO19991071A 1996-09-06 1999-03-04 N-substituerte indol-3-glyoksylamider, deres fremstilling, anvendelse for fremstilling av medikamenter, legemidler inneholdende disse samt en fremgangsmate for fremstilling av et legemiddel NO314725B3 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19636150A DE19636150A1 (de) 1996-09-06 1996-09-06 N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
PCT/EP1997/004474 WO1998009946A1 (de) 1996-09-06 1997-08-16 N-substituierte indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender wirkung

Publications (4)

Publication Number Publication Date
NO991071D0 NO991071D0 (no) 1999-03-04
NO991071L true NO991071L (no) 1999-03-04
NO314725B1 NO314725B1 (no) 2003-05-12
NO314725B3 NO314725B3 (no) 2009-03-09

Family

ID=7804772

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19991071A NO314725B3 (no) 1996-09-06 1999-03-04 N-substituerte indol-3-glyoksylamider, deres fremstilling, anvendelse for fremstilling av medikamenter, legemidler inneholdende disse samt en fremgangsmate for fremstilling av et legemiddel
NO20030481A NO20030481D0 (no) 1996-09-06 2003-01-30 N-substituerte indol-3-glyoksylamider med antiastmatisk, antiallergisk og immunundertrykkende/immunmodulerende virkning

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20030481A NO20030481D0 (no) 1996-09-06 2003-01-30 N-substituerte indol-3-glyoksylamider med antiastmatisk, antiallergisk og immunundertrykkende/immunmodulerende virkning

Country Status (27)

Country Link
US (4) US6008231A (no)
EP (1) EP0931063B3 (no)
JP (1) JP3296437B2 (no)
KR (1) KR100516321B1 (no)
CN (3) CN100376554C (no)
AR (1) AR008630A1 (no)
AT (1) ATE342889T1 (no)
AU (1) AU726521B2 (no)
BR (1) BR9712808B1 (no)
CA (1) CA2215013C (no)
CZ (1) CZ302301B6 (no)
DE (2) DE19636150A1 (no)
DK (1) DK0931063T5 (no)
ES (1) ES2276433T7 (no)
HK (3) HK1021641A1 (no)
HU (1) HU227797B1 (no)
IL (1) IL127798A (no)
NO (2) NO314725B3 (no)
NZ (1) NZ334476A (no)
PT (1) PT931063E (no)
RU (1) RU2237661C2 (no)
SK (1) SK285618B6 (no)
TR (1) TR199900469T2 (no)
TW (1) TW550256B (no)
UA (1) UA60312C2 (no)
WO (1) WO1998009946A1 (no)
ZA (1) ZA977475B (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
EE200000573A (et) * 1998-03-31 2002-04-15 The Institutes For Pharmaceutical Discovery, Llc Asendatud indoolalkaanhapped
DE19946301A1 (de) 1998-04-02 2001-04-19 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
CZ302588B6 (cs) * 1998-04-02 2011-07-27 Ziopharm Oncology, Inc. Použití N-substituovaného indol-3-glyoxylamidu pro výrobu léciva
DE19917504A1 (de) * 1999-04-17 2000-10-19 Dresden Arzneimittel Verwendung von Hydroxyindolen, die Inhibitoren der Phosphodiesterase 4 sind, zur Therapie chronisch obstruktiver Lungenerkrankungen
DE19818964A1 (de) * 1998-04-28 1999-11-04 Dresden Arzneimittel Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phospodiesterase 4 und Verfahren zu deren Herstellung
HUP0101625A3 (en) * 1998-04-28 2002-12-28 Elbion Ag New hydroxyindoles, their use as phosphodiesterase 4 inhibitors and method for producing same
SK287231B6 (sk) 1999-08-21 2010-04-07 Nycomed Gmbh Liečivo zahŕňajúce PDE inhibítor a agonistu beta2 adrenoreceptora
TWI269654B (en) * 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
DE10022925A1 (de) * 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
DE10037310A1 (de) * 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
JP2005504790A (ja) * 2001-09-13 2005-02-17 シンタ ファーマスーティカルズ コーポレイション 癌を治療するための３−グリオキシリルアミドインドール
US6903104B2 (en) * 2001-12-06 2005-06-07 National Health Research Institutes Indol-3-YL-2-oxoacetamide compounds and methods of use thereof
KR20050026002A (ko) * 2002-07-26 2005-03-14 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 치환된 인돌알칸산 유도체 및 이를 함유하는 당뇨 합병증치료용 제형
US7122674B2 (en) * 2002-08-01 2006-10-17 Elbion Ag Process for preparing high-purity hydroxyindolylglyoxylamides
DE10253426B4 (de) * 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
DE10318609A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 5-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
DE10318610A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 7-Azaindole und deren Verwendung als Therapeutika
DE10318611A1 (de) 2003-04-24 2004-11-11 Elbion Ag 4-, 6- oder 7-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
US20050075364A1 (en) * 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
JP4895811B2 (ja) 2003-09-11 2012-03-14 ケミア，インコーポレイテッド サイトカイン阻害剤
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
DE102004031538A1 (de) * 2004-06-29 2006-02-09 Baxter International Inc., Deerfield Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
JP2008519036A (ja) * 2004-11-08 2008-06-05 バクスター・インターナショナル・インコーポレイテッド チューブリン阻害化合物のナノ粒子組成物
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
EP1848430B1 (en) 2004-12-31 2017-08-02 Dr. Reddy's Laboratories Ltd. Novel benzylamine derivatives as cetp inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
JP2006247963A (ja) * 2005-03-09 2006-09-21 Oji Paper Co Ltd インクジェット記録用シート
EP1865949B1 (en) * 2005-03-11 2012-11-14 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7328672B2 (en) 2005-04-29 2008-02-12 Tendik Development, Llc Radial impulse engine, pump, and compressor systems, and associated methods of operation
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
US7598380B2 (en) * 2005-08-03 2009-10-06 Bristol-Myers Squibb Company Method of preparation of azaindole derivatives
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
PL2359826T3 (pl) 2006-07-05 2014-04-30 Astrazeneca Ab Połączenie inhibitora reduktazy HMG-CoA rosuwastatyny z inhibitorem fosfodiesterazy 4, takim jak roflumilast, N-tlenek roflumilastu, do leczenia chorób zapalnych płuc
JP5406716B2 (ja) 2006-08-07 2014-02-05 アイアンウッド ファーマシューティカルズ インコーポレイテッド インドール化合物
EP2066619A2 (en) * 2006-11-02 2009-06-10 Arete Therapeutics, INC. Soluble epoxide hydrolase inhibitors
WO2008066807A1 (en) * 2006-11-28 2008-06-05 Ziopharm Oncology, Inc. Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
RU2624506C2 (ru) 2009-04-29 2017-07-04 АМАРИН КОРПОРЕЙШН ПиЭлСи Фармацевтические композиции, содержащие ера и сердечно-сосудистое средство, и способы их применения
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
MX2014001849A (es) 2011-08-18 2014-10-24 Reddys Lab Ltd Dr Compuestos de amina heterociclicos sustituidos como inhibidores de proteina de transferencia de ester colesterilo (cetp).
CN103958511A (zh) 2011-09-27 2014-07-30 雷迪博士实验室有限公司 作为胆固醇酯转移蛋白(CETP)抑制剂用于治疗动脉粥样硬化的5-苄基氨基甲基-6-氨基吡唑并[3,4-b]吡啶衍生物
EP3165224A1 (en) 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
CN109000634B (zh) * 2018-06-04 2022-06-03 上海智蕙林医疗科技有限公司 一种导航对象行进路线的提醒方法和***

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB797258A (en) * 1955-04-11 1958-06-25 Upjohn Co 3-substituted indoles
GB944443A (no) * 1959-09-25 1900-01-01
GB1028812A (en) * 1962-08-28 1966-05-11 Ici Ltd Indole derivatives
GB1089071A (en) * 1964-02-28 1967-11-01 Merck & Co Inc Indole derivatives
US3686213A (en) * 1970-08-28 1972-08-22 American Cyanamid Co Substituted aminoethyl indoles
FR2689888B1 (fr) * 1992-04-10 1994-06-10 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
ES2377223T3 (es) * 1994-04-01 2012-03-23 Eli Lilly And Company Éster metílico de ácido [[3-(2-amino-1,2-dioxoetil)-2-etil-1-(fenilmetil)-11H-indol-4-IL]oxi]acético como inhibidor de sPLA2
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
DE19946301A1 (de) * 1998-04-02 2001-04-19 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
US7205299B2 (en) * 2003-06-05 2007-04-17 Zentaris Gmbh Indole derivatives having an apoptosis-inducing effect

Also Published As

Publication number Publication date
CN101219985B (zh) 2011-04-27
CN1227542A (zh) 1999-09-01
UA60312C2 (uk) 2003-10-15
KR20000068495A (ko) 2000-11-25
JP3296437B2 (ja) 2002-07-02
HK1021641A1 (en) 2000-06-23
AR008630A1 (es) 2000-02-09
PT931063E (pt) 2007-02-28
CN100488948C (zh) 2009-05-20
DK0931063T5 (da) 2010-01-11
CZ61699A3 (cs) 1999-06-16
NO991071D0 (no) 1999-03-04
SK285618B6 (sk) 2007-05-03
ES2276433T3 (es) 2007-06-16
US6344467B1 (en) 2002-02-05
HUP9903741A3 (en) 2001-01-29
ATE342889T1 (de) 2006-11-15
HK1123280A1 (en) 2009-06-12
IL127798A0 (en) 1999-10-28
RU2237661C2 (ru) 2004-10-10
NO20030481L (no) 1999-03-04
DE59712752D1 (de) 2006-11-30
NO314725B3 (no) 2009-03-09
AU4015897A (en) 1998-03-26
WO1998009946A1 (de) 1998-03-12
DK0931063T3 (da) 2007-02-19
JP2000505098A (ja) 2000-04-25
ZA977475B (en) 1998-02-19
US6919344B2 (en) 2005-07-19
NO20030481D0 (no) 2003-01-30
BR9712808B1 (pt) 2009-05-05
DE19636150A1 (de) 1998-03-12
CA2215013A1 (en) 1998-03-06
NO314725B1 (no) 2003-05-12
AU726521C (en) 1998-03-26
US6008231A (en) 1999-12-28
US20020161025A1 (en) 2002-10-31
AU726521B2 (en) 2000-11-09
CN1496980A (zh) 2004-05-19
IL127798A (en) 2003-07-31
EP0931063B1 (de) 2006-10-18
NZ334476A (en) 2000-05-26
CN101219985A (zh) 2008-07-16
EP0931063B3 (de) 2009-04-08
BR9712808A (pt) 1999-11-23
CN100376554C (zh) 2008-03-26
EP0931063A1 (de) 1999-07-28
ES2276433T7 (es) 2009-11-05
HU227797B1 (en) 2012-03-28
SK27199A3 (en) 1999-08-06
CZ302301B6 (cs) 2011-02-09
US20030207892A1 (en) 2003-11-06
HK1064379A1 (en) 2005-01-28
TR199900469T2 (xx) 1999-05-21
KR100516321B1 (ko) 2005-09-23
TW550256B (en) 2003-09-01
HUP9903741A2 (hu) 2000-04-28
CA2215013C (en) 2002-03-05

Similar Documents

Publication Publication Date Title
NO20030481D0 (no) N-substituerte indol-3-glyoksylamider med antiastmatisk, antiallergisk og immunundertrykkende/immunmodulerende virkning
DE69732084D1 (de) Pulsladeverfahren und ladegerät
DE59711118D1 (de) Spickeln, Zunehmen und Mindern
DE69532501D1 (de) Verbessertes, langwirkendes gastrointestinales und ösophagisches schutzmittel
ZA976222B (en) N-(4-aryl-thiazol-2-yl)-sulphonamide derivatives and their use.
DE69738197D1 (de) Azolotriazine und pyrimidine
DE69534181D1 (de) System mit Endgerät und Karte, Karte und Endgerät
NO970412D0 (no) Indol-, indazol-, pyridopyrrol- og pyridopyrazol-derivater med antiastmatisk, antiallergisk, anti-inflammatorisk og immunomodulerende virkning
FI961154A (fi) Menetelmä ja järjestely matkapuhelimen käytön rajoittamiseksi
DE69534816D1 (de) Integrale radio- und infrarot-hörhilfevorrichtung
DE69526002T2 (de) Aufladegerät und Aufladevorrichtung
NO971076D0 (no) Totrinns filtreringssystem med keramisk skum, og fremgangsmåte
DE69727047D1 (de) Entpaketierer und rahmenausgleicher damit
NO964541L (no) Porphacyanin og CNC-utvidete porphyriner
DE69713817D1 (de) Schutzabdeckung und damit ausgestatteter Apparat
DE69527045T2 (de) Tetrahydrofurane und tetrahydropyrane
DE69532056D1 (de) Signalgenerator und drahtloses Mobilsystem damit
DE59706929D1 (de) Balancier-Hebegerät
DE69842206D1 (de) Echounterdrücker und echounterdrückungsverfahren
NO20003268D0 (no) Hyperhydrert kitikolin, fremgangsmÕte og anvendelse
DE69420653T2 (de) Verstärkerkette in Strommode, Operationsverstärker, Verstärkungszelle und zugehöriges Verstärkerelement
IS4987A (is) PTX næm G prótein, framleiðsla þeirra og notkun
DE29618427U1 (de) Tragbarer und rollender Ranzen
DE69809829T2 (de) Untergrunderkennung und Kompensation
BR7603058U (pt) Telefone celular econõmico seguro e corretivo

Legal Events

Date Code Title Description
LC4 Limitation of patent rights - b3 (par. 39b patent act)
MM1K Lapsed by not paying the annual fees